0
Détail de l'auteur
Auteur T. Lancaster |
Documents disponibles écrits par cet auteur (9)
Ajouter le résultat dans votre panier Affiner la rechercheCombined pharmacotherapy and behavioural interventions for smoking cessation (Review) / Lindsay F. Stead (2012)
Titre : Combined pharmacotherapy and behavioural interventions for smoking cessation (Review) Type de document : texte imprimé Auteurs : Lindsay F. Stead, Auteur ; T. Lancaster, Auteur Editeur : The Cochrane Collaboration Année de publication : 2012 Collection : Cochrane Database of Systematic Reviews Importance : 90 p. Langues : Français (fre) Catégories : [TABAC] sevrage tabagique:aide au sevrage:aide psychologique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologiqueIndex. décimale : TA 6.2 Méthodes individuelles En ligne : https://doi.org/10.1002/14651858.CD008286.pub3 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7443 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Group behaviour therapy programmes for smoking cessation (review) Type de document : texte imprimé Auteurs : Lindsay F. Stead, Auteur ; T. Lancaster, Auteur Editeur : The Cochrane Collaboration Année de publication : 20/04/2005 Collection : Cochrane Database of Systematic Reviews num. 3 Note générale : Dans la bibliothèque virtuelle (articles scientifiques) Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:aide au sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode collectiveIndex. décimale : TA 6.3.1 Animation de groupes Résumé : Attending group smoking cessation programmes helps smokers to quit. Group programmes are more effective for helping people to stop smoking than being given self-help materials without face-to-face instruction and group support. The chances of quitting are more than doubled. It is unclear whether groups are better than individual counselling or other advice, but are more effective than no treatment. Not all smokers making a quit attempt want to attend group meetings, but for those who do they are likely to be helpful. En ligne : https://doi.org/10.1002/14651858.CD001007.pub2 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3007 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002103 TA 6.3.1 STE G Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Individual behavioural counselling for smoking cessation : Review Type de document : texte imprimé Auteurs : T. Lancaster, Auteur ; Lindsay F. Stead, Auteur Année de publication : 2009 Importance : 36 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] tabagisme:habitude tabagique Index. décimale : TA 6.2 Méthodes individuelles Résumé : BACKGROUND:
Individual counselling from a smoking cessation specialist may help smokers to make a successful attempt to stop smoking.
OBJECTIVES:
The objective of the review is to determine the effects of individual counselling.
SEARCH STRATEGY:
We searched the Cochrane Tobacco Addiction Group Specialized Register for studies with counsel* in any field. Date of the most recent search: December 2004.
SELECTION CRITERIA:
Randomized or quasi-randomized trials with at least one treatment arm consisting of face-to-face individual counselling from a healthcare worker not involved in routine clinical care. The outcome was smoking cessation at follow up at least six months after the start of counselling.
DATA COLLECTION AND ANALYSIS:
Both authors extracted data. The intervention and population, method of randomization and completeness of follow up were recorded.
MAIN RESULTS:
We identified 21 trials with over 7000 participants. Eighteen trials compared individual counselling to a minimal behavioural intervention, four compared different types or intensities of counselling. Individual counselling was more effective than control. The odds ratio for successful smoking cessation was 1.56 (95% confidence interval 1.32 to 1.84). In a subgroup of three trials where all participants received nicotine replacement therapy the point estimate of effect was smaller and did not reach significance (odds ratio 1.34, 95% confidence interval 0.98 to 1.83). We failed to detect a greater effect of intensive counselling compared to brief counselling (odds ratio 0.98, 95% confidence interval 0.61 to 1.56).En ligne : https://www.ncsct.co.uk/usr/pub/individual-behaviour-counselling.pdf Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7964 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Interventions for preventing tobacco sales to minors Type de document : texte imprimé Auteurs : Lindsay F. Stead, Auteur ; T. Lancaster, Auteur Editeur : The Cochrane Collaboration Année de publication : 2008 Collection : Cochrane Database of Systematic Reviews num. 3 Importance : 10 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] législation:législation antitabac:interdiction de vente aux mineursIndex. décimale : TA 5.3 Programmes Résumé : BACKGROUND:
Laws restricting sales of tobacco products to minors exist in many countries, but young people may still purchase cigarettes easily.
OBJECTIVES:
The review assesses the effects of interventions to reduce underage access to tobacco by deterring shopkeepers from making illegal sales.
SEARCH STRATEGY:
We searched the Cochrane Tobacco Addiction group trials register, MEDLINE and EMBASE. Date of the most recent searches: September 2004.
SELECTION CRITERIA:
We included controlled trials and uncontrolled studies with pre- and post intervention assessment of interventions to change retailers' behaviour. The outcomes were changes in retailer compliance with legislation (assessed by test purchasing), changes in young people's smoking behaviour, and perceived ease of access to tobacco products.
DATA COLLECTION AND ANALYSIS:
One reviewer prescreened studies for relevance, and both reviewers independently assessed the studies for inclusion. One reviewer extracted data from included studies and the second checked them. Study designs and types of intervention were heterogeneous so results were synthesized narratively, with greater weight given to controlled studies.
MAIN RESULTS:
We identified 34 studies of which 14 had data from a control group for at least one outcome. Giving retailers information was less effective in reducing illegal sales than active enforcement or multicomponent educational strategies, or both. No strategy achieved complete, sustained compliance. In three controlled trials, there was little effect of intervention on youth perceptions of access or prevalence of smoking.
AUTHORS' CONCLUSIONS:
Interventions with retailers can lead to large decreases in the number of outlets selling tobacco to youths. However, few of the communities studied in this review achieved sustained levels of high compliance. This may explain why there is limited evidence for an effect of intervention on youth perception of ease of access to tobacco, and on smoking behaviour.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8090 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005639 5.3 STE I Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Nicotine receptor partial agonists for smoking cessation (review) Type de document : texte imprimé Auteurs : Kate Cahill, Auteur ; Lindsay F. Stead, Auteur ; T. Lancaster, Auteur Editeur : The Cochrane Collaboration Année de publication : 2008 Collection : Cochrane Database of Systematic Reviews Importance : 60 p. Langues : Français (fre) Catégories : [TABAC] chimie du tabac:constituant:alcaloïde:nicotine:récepteur nicotinique
[TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to
counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was
developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation.
The first trial reports of varenicline were released in 2006, and further trials have now been published or are currently are underway.En ligne : https://doi.org/10.1002/14651858.CD006103.pub8 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7881 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002133 TA 6.2.3.1.4 CAH N Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Nicotine replacement therapy versus control for smoking cessation Type de document : document électronique Auteurs : Jamie Hartmann-Boyce, Auteur ; Samantha C. Chepkin, Auteur ; Weiyu Ye, Auteur ; Christopher Bullen, Auteur ; T. Lancaster, Auteur Editeur : The Cochrane Collaboration Année de publication : 2018 Collection : Cochrane Database of Systematic Reviews num. 5 Importance : 197 p. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique Index. décimale : TA 6.2.3.1 Substitution nicotinique Résumé : Il existe des données probantes de haute qualité indiquant que toutes les formes homologuées de TSN (Thérapies de Substitution Nicotinique - chewing‐gums, patchs transdermique, vaporisateur nasal, inhalateur et comprimés/pastilles sublinguaux) peuvent aider les personnes qui tentent d'arrêter de fumer à augmenter leurs chances de succès. Les TSN augmentent le taux d'abandon de 50 % à 60 %, quel que soit le contexte, et il est très peu probable que d'autres recherches modifient notre confiance dans l'estimation de l'effet. L'efficacité relative de la TSN semble être largement indépendante de l'intensité du soutien supplémentaire fourni à l'individu. L'apport d'un soutien plus intense n'est pas essentiel au succès de la TSN, même s'il facilite le sevrage. La TSN cause souvent une irritation mineure du site par lequel elle est administrée et, dans de rares cas, peut causer des douleurs thoraciques non ischémiques et des palpitations. En ligne : https://doi.org/10.1002/14651858.CD000146.pub5 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10345 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Pharmacological interventions for smoking cessation : an overview and network meta-analysis (review) Type de document : texte imprimé Auteurs : Kate Cahill, Auteur ; S. Stevens, Auteur ; T. Lancaster, Auteur ; R. Perera, Auteur Editeur : The Cochrane Collaboration Année de publication : 2013 Collection : Cochrane Database of Systematic Reviews num. issue 5 Importance : 49 p. Langues : Français (fre) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologiqueIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Abstract
Background
Smoking is the leading preventable cause of illness and premature death worldwide. Some medications have been proven to help people to quit, with three licensed for this purpose in Europe and the USA: nicotine replacement therapy (NRT), bupropion, and varenicline. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries. Other therapies, including nortriptyline, have also been tested for effectiveness.
Objectives
How do NRT, bupropion and varenicline compare with placebo and with each other in achieving long-term abstinence (six months or longer)?
How do the remaining treatments compare with placebo in achieving long-term abstinence?
How do the risks of adverse and serious adverse events (SAEs) compare between the treatments, and are there instances where the harms may outweigh the benefits?
Methods
The overview is restricted to Cochrane reviews, all of which include randomised trials. Participants are usually adult smokers, but we exclude reviews of smoking cessation for pregnant women and in particular disease groups or specific settings. We cover nicotine replacement therapy (NRT), antidepressants (bupropion and nortriptyline), nicotine receptor partial agonists (varenicline and cytisine), anxiolytics, selective type 1 cannabinoid receptor antagonists (rimonabant), clonidine, lobeline, dianicline, mecamylamine, Nicobrevin, opioid antagonists, nicotine vaccines, and silver acetate. Our outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment. Our outcome for harms is the incidence of serious adverse events associated with each of the treatments.
We searched the Cochrane Database of Systematic Reviews (CDSR) in The Cochrane Library, for any reviews with 'smoking' in the title, abstract or keyword fields. The last search was conducted in November 2012. We assessed methodological quality using a revised version of the AMSTAR scale. For NRT, bupropion and varenicline we conducted network meta-analyses, comparing each with the others and with placebo for benefit, and varenicline and bupropion for risks of serious adverse events.
Main results
We identified 12 treatment-specific reviews. The analyses covered 267 studies, involving 101,804 participants. Both NRT and bupropion were superior to placebo (odds ratios (OR) 1.84; 95% credible interval (CredI) 1.71 to 1.99, and 1.82; 95% CredI 1.60 to 2.06 respectively). Varenicline increased the odds of quitting compared with placebo (OR 2.88; 95% CredI 2.40 to 3.47). Head-to-head comparisons between bupropion and NRT showed equal efficacy (OR 0.99; 95% CredI 0.86 to 1.13). Varenicline was superior to single forms of NRT (OR 1.57; 95% CredI 1.29 to 1.91), and to bupropion (OR 1.59; 95% CredI 1.29 to 1.96).
Varenicline was more effective than nicotine patch (OR 1.51; 95% CredI 1.22 to 1.87), than nicotine gum (OR 1.72; 95% CredI 1.38 to 2.13), and than 'other' NRT (inhaler, spray, tablets, lozenges; OR 1.42; 95% CredI 1.12 to 1.79), but was not more effective than combination NRT (OR 1.06; 95% CredI 0.75 to 1.48). Combination NRT also outperformed single formulations. The four categories of NRT performed similarly against each other, apart from 'other' NRT, which was marginally more effective than NRT gum (OR 1.21; 95% CredI 1.01 to 1.46).
Cytisine (a nicotine receptor partial agonist) returned positive findings (risk ratio (RR) 3.98; 95% CI 2.01 to 7.87), without significant adverse events or SAEs.
Across the 82 included and excluded bupropion trials, our estimate of six seizures in the bupropion arms versus none in the placebo arms was lower than the expected rate (1:1000), at about 1:1500. SAE meta-analysis of the bupropion studies demonstrated no excess of neuropsychiatric (RR 0.88; 95% CI 0.31 to 2.50) or cardiovascular events (RR 0.77; 95% CI 0.37 to 1.59). SAE meta-analysis of 14 varenicline trials found no difference between the varenicline and placebo arms (RR 1.06; 95% CI 0.72 to 1.55), and subgroup analyses detected no significant excess of neuropsychiatric events (RR 0.53; 95% CI 0.17 to 1.67), or of cardiac events (RR 1.26; 95% CI 0.62 to 2.56).
Nortriptyline increased the chances of quitting (RR 2.03; 95% CI 1.48 to 2.78). Neither nortriptyline nor bupropion were shown to enhance the effect of NRT compared with NRT alone. Clonidine increased the chances of quitting (RR 1.63; 95% CI 1.22 to 2.18), but this was offset by a dose-dependent rise in adverse events. Mecamylamine in combination with NRT may increase the chances of quitting, but the current evidence is inconclusive. Other treatments failed to demonstrate a benefit compared with placebo. Nicotine vaccines are not yet licensed for use as an aid to smoking cessation or relapse prevention. Nicobrevin's UK license is now revoked, and the manufacturers of rimonabant, taranabant and dianicline are no longer supporting the development or testing of these treatments.
Authors' conclusions
NRT, bupropion, varenicline and cytisine have been shown to improve the chances of quitting. Combination NRT and varenicline are equally effective as quitting aids. Nortriptyline also improves the chances of quitting. On current evidence, none of the treatments appear to have an incidence of adverse events that would mitigate their use.
Further research is warranted into the safety of varenicline and into cytisine's potential as an effective and affordable treatment, but not into the efficacy and safety of NRT.En ligne : https://doi.org/10.1002/14651858.CD009329.pub2 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7444 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Relapse prevention interventions for smoking cessation Type de document : texte imprimé Auteurs : Peter Hajek, Auteur ; Lindsay F. Stead, Auteur ; Robert West, Auteur ; Martin J. Jarvis, Auteur ; T. Lancaster, Auteur Année de publication : 2009 Importance : 76 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:efficacité du sevrage:rechuteIndex. décimale : TA 6.5 Rechutes Résumé : Contexte Un certain nombre de traitements peuvent aider les fumeurs à réussir leur tentative d’arrêt, mais bon nombre de ceux qui ont cessé de fumer au départ rechutent avec le temps. Plusieurs interventions ont été proposées pour aider à prévenir les rechutes. Objectifs Déterminer si des interventions spécifiques de prévention des rechutes réduisent la proportion de personnes ayant récemment cessé de fumer qui recommencent à fumer. Méthodes de recherche En août 2008, nous avons consulté le registre des essais du groupe de lutte contre le tabagisme dans le groupe Cochrane sur le tabac. maintien en titre, résumés ou mots-clés. Les critères de sélection Essais contrôlés randomisés ou quasi-randomisés d'interventions de prévention des rechutes avec un suivi minimum de six mois. nous incluaient les fumeurs qui avaient arrêté de fumer seuls ou suivaient une abstinence forcée ou qui participaient à des programmes de traitement. Nous avons inclus des essais comparant des interventions de prévention des rechutes à des interventions sans intervention ou comparant un programme de sevrage tabagique. avec des éléments supplémentaires de prévention des rechutes à un programme de cessation uniquement. Collecte et analyse de données Les études ont été examinées et les données extraites par un auteur et vérifiées par un second. Les désaccords ont été résolus par discussion ou par renvoi à un troisième auteur. Principaux résultats Cinquante-quatre études répondaient aux critères d'inclusion, mais étaient hétérogènes en termes de population et d'interventions. Nous avons examiné 36 études les abstentionnistes randomisés séparément des études randomisant les participants avant leur date d'arrêt. En regardant des études d'interventions comportementales qui ont randomisé les abstinents, nous n'avons détecté aucun bénéfice d'une rechute brève et «basée sur les compétences». méthodes de prévention pour les femmes qui avaient cessé de fumer en raison d'une grossesse ou pour les fumeuses en période d'abstinence forcée pendant l'hospitalisation ou l'entraînement militaire. Nous n’avons pas non plus détecté d’effets significatifs d’interventions comportementales lors d’essais chez des patients non sélectionnés. groupes de fumeurs qui ont cessé de fumer seuls ou avec un programme officiel. Parmi les essais randomisant les fumeurs avant leur date d'arrêt En ligne : https://doi.org/10.1002/14651858.CD003999.pub6 Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8828 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Stage-based interventions for smoking cessation Type de document : texte imprimé Auteurs : Kate Cahill, Auteur ; T. Lancaster, Auteur ; Natasha Green, Auteur Editeur : The Cochrane Collaboration Année de publication : 2010 Collection : Cochrane Database of Systematic Reviews num. 11 Importance : 3 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:entretien motivationnel:modèle transthéoriqueIndex. décimale : TA 6.2.2.1 Méthode comportementale Résumé : BACKGROUND:
The transtheoretical model is the most widely known of several stage-based theories of behaviour. It proposes that smokers move through a discrete series of motivational stages before they quit successfully. These are precontemplation (no thoughts of quitting), contemplation (thinking about quitting), preparation (planning to quit in the next 30 days), action (quitting successfully for up to six months), and maintenance (no smoking for more than six months). According to this influential model, interventions which help people to stop smoking should be tailored to their stage of readiness to quit, and are designed to move them forward through subsequent stages to eventual success. People in the preparation and action stages of quitting would require different types of support from those in precontemplation or contemplation.
OBJECTIVES:
Our primary objective was to test the effectiveness of stage-based interventions in helping smokers to quit.
SEARCH STRATEGY:
We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('stage* of change', 'transtheoretical model*', 'trans-theoretical model*, 'precaution adoption model*', 'health action model', 'processes of change questionnaire*', 'readiness to change', 'tailor*') and 'smoking' in the title or abstract, or as keywords. The latest search was in August 2010.
SELECTION CRITERIA:
We included randomized controlled trials, which compared stage-based interventions with non-stage-based controls, with 'usual care' or with assessment only. We excluded trials which did not report a minimum follow-up period of six months from start of treatment, and those which measured stage of change but did not modify their intervention in the light of it.
DATA COLLECTION AND ANALYSIS:
We extracted data in duplicate on the participants, the dose and duration of intervention, the outcome measures, the randomization procedure, concealment of allocation, and completeness of follow up.The main outcome was abstinence from smoking for at least six months. We used the most rigorous definition of abstinence, and preferred biochemically validated rates where reported. Where appropriate we performed meta-analysis to estimate a pooled risk ratio, using the Mantel-Haenszel fixed-effect model.
MAIN RESULTS:
We found 41 trials (>33,000 participants) which met our inclusion criteria. Four trials, which directly compared the same intervention in stage-based and standard versions, found no clear advantage for the staging component. Stage-based versus standard self-help materials (two trials) gave a relative risk (RR) of 0.93 (95% CI 0.62 to 1.39). Stage-based versus standard counselling (two trials) gave a relative risk of 1.00 (95% CI 0.82 to 1.22). Six trials of stage-based self-help systems versus any standard self-help support demonstrated a benefit for the staged groups, with an RR of 1.27 (95% CI 1.01 to 1.59). Twelve trials comparing stage-based self help with 'usual care' or assessment-only gave an RR of 1.32 (95% CI 1.17 to 1.48). Thirteen trials of stage-based individual counselling versus any control condition gave an RR of 1.24 (95% CI 1.08 to 1.42). These findings are consistent with the proven effectiveness of these interventions in their non-stage-based versions. The evidence was unclear for telephone counselling, interactive computer programmes or training of doctors or lay supporters. This uncertainty may be due in part to smaller numbers of trials.
AUTHORS' CONCLUSIONS:
Based on four trials using direct comparisons, stage-based self-help interventions (expert systems and/or tailored materials) and individual counselling were neither more nor less effective than their non-stage-based equivalents. Thirty-one trials of stage-based self help or counselling interventions versus any control condition demonstrated levels of effectiveness which were comparable with their non-stage-based counterparts. Providing these forms of practical support to those trying to quit appears to be more productive than not intervening. However, the additional value of adapting the intervention to the smoker's stage of change is uncertain. The evidence is not clear for other types of staged intervention, including telephone counselling, interactive computer programmes and training of physicians or lay supporters. The evidence does not support the restriction of quitting advice and encouragement only to those smokers perceived to be in the preparation and action stages.En ligne : https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004492.pub4/full Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8079 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005631 TA 6.2.2.1 CAH S Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
